hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06355518 id: INu-RC briefTitle: Pre-operative Immuno-Nutrition in Radical Cystectomy acronym: INu-RC overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-09 date: 2026-09 date: 2024-04-09 date: 2024-04-09 name: Fondazione IRCCS Policlinico San Matteo di Pavia class: OTHER name: IRCCS Ospedale San Raffaele briefSummary: This study will evaluate the effect of preoperative oral immunonutrition on postoperative complications in patients undergoing radical cystectomy for bladder cancer. Patients receiving preoperative immunonutrition will be compared to controls receiving a standard high-calorie, high-protein oral nutritional supplement. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 260 type: ESTIMATED name: Immunonutrition name: Standard Oral Nutritional Supplement measure: 30-day complications measure: 30-day severe complications measure: 90-day severe complications measure: 30-day and 90-day infectious complications measure: 30-day and 90-day occurrence of other medical conditions measure: Time to recovery of bowel function measure: Time to postoperative mobilization measure: Muscular strength modifications measure: Weight modifications measure: Biochemical nutritional indexes modifications measure: Need of blood transfusions measure: Length of stay measure: Readmission rate measure: 30-day and 90-day mortality measure: Compliance measure: Tolerability (gastrointestinal symptoms related to nutritional supplement) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Ospedale San Raffaele city: Milan zip: 20132 country: Italy name: Bettiga Arianna role: CONTACT email: bettiga.arianna@hsr.it name: Marco Moschini, MD role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 facility: Fondazione IRCCS Policlinico San Matteo city: Pavia zip: 27100 country: Italy name: Ferrari Alessandra, PharmD role: CONTACT phone: +390382503689 email: alessandra.ferrari@smatteo.pv.it name: Valentina Da Prat, MD role: PRINCIPAL_INVESTIGATOR lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06355505 id: PREPS-21-0098 briefTitle: Process of Emergence and Implementation of Advanced Practice Nursing in France acronym: PEIPA overallStatus: RECRUITING date: 2024-03-01 date: 2028-01-01 date: 2028-03-01 date: 2024-04-09 date: 2024-04-09 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Longitudinal, observational research with a mixed quantitative (by questionnaires) and qualitative (by interviews and observations) approach, multidisciplinary, among Advanced Practice Nurses (APNs) already graduated and 3 consecutive classes of advanced practice students who will be followed annually during their implementation as APN until the last year of the study. The questionnaires will focus on APN scope of practice evolution, economical analysis and geographical distribution of APN. The ethnographical approach will assess APN settlements and relation with healthcare colleagues and patients. conditions: Nurse's Role studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 1600 type: ESTIMATED measure: Factors influencing the effective implementation of advanced practice nursing in France in primary care and health facilities measure: Mapping of APNs in France with socio-demographic data measure: Definition by the APN of its role and missions measure: Implementation and dissemination of the APN practice in the territory according to the context of practice (community care, hospital) measure: Identification of potential impact dimensions of Advanced Practice Nursing sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beaujon hospital status: RECRUITING city: Clichy zip: 92110 country: France name: Julie Devictor, PhD role: CONTACT phone: 06 64 71 26 75 email: julie.devictor@aphp.fr name: Anne Leclercq, PhD role: CONTACT phone: 0033 7 62 70 58 05 email: anne.leclercq2@aphp.fr lat: 48.90018 lon: 2.30952 hasResults: False
nctId: NCT06355492 id: 2090/10/30 briefTitle: Virtual Reality Distraction in Pediatric Patients. overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06 date: 2025-07 date: 2024-04-09 date: 2024-04-09 name: Tanta University class: OTHER briefSummary: The aim of this study is to evaluate the effect of virtual reality distraction on pain and anxiety during infiltration anesthesia in pediatric patients. conditions: Virtual Reality conditions: Distraction conditions: Infiltration Anesthesia conditions: Pediatric Patients studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 150 type: ESTIMATED name: Virtual reality goggles (VR ) name: regular screen measure: Assessment of pain during virtual reality distraction sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Rokia Abdelrhman Saad Elfaramawy city: Tanta state: El-Gharbia zip: 31527 country: Egypt name: Rokia A Elfaramawy, BDS role: CONTACT phone: 01069823221 email: Rokiaabdelrahman94@gmail.com name: Fatma A Elhendawy, Professor role: SUB_INVESTIGATOR name: Nura I Abozena, Lecturer role: SUB_INVESTIGATOR lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06355479 id: HY1001-2022-P3 briefTitle: A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia overallStatus: COMPLETED date: 2023-04-10 date: 2023-11-22 date: 2023-12-12 date: 2024-04-09 date: 2024-04-09 name: Healthgen Biotechnology Corp. class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA. The main question it aims to answer is whether OsrHSA is effective in elevating the serum albumin level of cirrhotic patients with hypoalbuminemia.
nctId: NCT06355466 id: 51-112334 briefTitle: Tunneled Hemodialysis Catheters as Permanent Vascular Access: Evaluating One-year Patency Rate and Affecting Factors overallStatus: COMPLETED date: 2022-01-09 date: 2023-08-11 date: 2023-08-28 date: 2024-04-09 date: 2024-04-09 name: Golestan University of Medical sciences class: OTHER briefSummary: In this prospective cross-sectional study, patients with ESRD unfit for AVF/AVG were scheduled for a right or left trans-jugular tunneled catheter placement. All patients were asked about their catheters' function one year after its implantation and the presumed affecting factors on catheters' patency were evaluated. conditions: Vascular Access Devices studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 156 type: ACTUAL measure: one year patency rate of hemodialysis catheters measure: one year patency rate of hemodialysis catheters in age subgroups measure: one year patency rate of hemodialysis catheters in diabetic patients measure: one year patency rate of hemodialysis catheters in hypertensive patients measure: one year patency rate of hemodialysis catheters in patients on antiplatelet drugs measure: one year patency rate of hemodialysis catheters in sex subgroups sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Golestan University of Medical Sciences, faculty of medicine city: Gorgan state: Golestan zip: 4918936316 country: Iran, Islamic Republic of lat: 36.8427 lon: 54.44391 hasResults: False
nctId: NCT06355453 id: 2023-090-MIC-GES briefTitle: Evaluation of the Goldcrest Patch Performance overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2024-08-30 date: 2024-12-31 date: 2024-04-09 date: 2024-04-09 name: GE Healthcare class: INDUSTRY briefSummary: The Novii Patch is an accessory to the Novii+ Pod that connects directly to the Novii+ Pod and contains the surface electrodes that attach to the abdomen.
The primary objective is to collect Data on Skin Integrity and Patch Adhesion Quality From the Patch After 18 Hours of Wear. The secondary objective is to evaluate fetal monitoring on adult pregnant females greater than 32 weeks gestation and non-pregnant females to collect data on electrical fetal, maternal, and uterine activity. conditions: Fetal Monitoring studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Goldcrest Patch and Three Patch Coupons name: Goldcrest Patch and Novii Patch measure: Primary Objective measure: Primary Objective measure: Secondary Objective measure: Secondary Objective measure: Incidence of Treatment-Emergent Adverse Events Objective sex: FEMALE minimumAge: 22 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355440 id: 2312288-16 briefTitle: Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China overallStatus: RECRUITING date: 2024-03-18 date: 2024-06-30 date: 2024-06-30 date: 2024-04-09 date: 2024-04-09 name: Fudan University class: OTHER briefSummary: The goal of this pilot study is to access the feasibility and impact of a financial navigation program on improving financial toxicity among patients with breast cancer in China.
* Strategies for holding a financial-related family meeting conditions: Breast Neoplasm Female conditions: Financial Toxicity conditions: Financial Navigation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Financial Navigation name: Usual Care measure: Eligibility rate measure: Consent rate measure: Retention rate measure: Adherence rate measure: Patient-reported satisfaction measure: Qualitative assessment of the intervention measure: Cost-related health literacy measure: Financial toxicity measure: Material domain of financial toxicity measure: Behavioral domain of financial toxicity sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai state: Shanghai zip: 200032 country: China name: Xiaoyi Yuan, Master role: CONTACT phone: (+86) 18918305439 email: 22211170009@m.fudan.edu.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06355427 id: 2023-507938-24-00 briefTitle: The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma acronym: FAPIChol overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2027-09-01 date: 2028-02-01 date: 2024-04-09 date: 2024-04-09 name: Mara Veenstra, MD class: OTHER name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) name: UMC Utrecht briefSummary: Background
Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually. Currently, surgical resection is the only curative option. However, patients are not eligible for surgery if the tumor cannot be resected or the cancer has spread. For this group of patients, palliative chemotherapy is the most suited treatment option. To find out if a patient is suited for surgery, CT and MRI are performed. These imaging techniques, however, struggle to correctly identify small cancer spreads that are smaller than 1 cm. Therefore, cancer that has already spread can be found during surgery. In these cases, the tumor cannot be removed and the surgery therefore has not been of any benefit for the patient. These surgeries could be avoided by implementing a diagnostic tool with significantly higher accuracy than those currently used. Single center studies have shown that fibroblast activation protein inhibitor (FAPI) PET-CT is a very promising technique for determining metastases in tumors with prominent desmoplastic reactions, like cholangiocarcinoma. The investigators predict that implementation of preoperative FAPI PET-CT could prevent futile surgery for at least half of patients in whom intra-operative metastasized disease is found using the current work-up.
Potential risks and burdens associated with this study are an extra hospital visit and a time burden of approximately half a day. Risks associated with administering FAPI are (re)bleed and infection. Both risks have a minimal probability of onset and can usually easily be treated. As \[18F\]F-FAPI is a sub-pharmacologically micro-dosed diagnostic tracer, the risk of allergic reactions is expected to be minimal and no tissue damage is expected. The burden associated with undergoing a PET-CT may be laying still for a certain time, and possible experience of claustrophobia. Possible metastases of the cancer will have to be confirmed when suspicious findings are seen on FAPI PET-CT. This could mean that participants will have to undergo additional testing such as imaging (CT or MRI) or biopsy. Undergoing FAPI PET-CT prior to surgery will result in a surgical delay when compared with the current clinical practice. The investigators do not expect this delay to influence the patient's prognosis. Follow-up will result in a time burden for patients to answer questionnaires on a two-weekly or monthly basis. conditions: Cholangiocarcinoma studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 81 type: ESTIMATED name: [18F]F-FAPI PET-CT measure: Diagnostic accuracy of [18F]F-FAPI PET-CT measure: Change of treatment measure: Cost-effectiveness measure: Number of additional significant findings using [18F]F-FAPI PET-CT measure: Number of times nuclear medicine specialists' [18F]F-FAPI PET-CT conclusions differed from one another measure: Number of lesions found on [18F]F-FAPI PET-CT measure: Number of days between [18F]F-FAPI PET-CT and exploratory surgery measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 measure: Number of participants in which dynamic [18F]F-FAPI PET-CT followed by conventional [18F]F-FAPI PET-CT was able to distinguish benign lesions from malignant lesions measure: Change in volume of interest (cm3) using dynamic [18F]F-FAPI PET-CT measure: Difference in SUVmax between dynamic and conventional [18F]F-FAPI PET-CT measure: Difference in SUVmean between dynamic and conventional [18F]F-FAPI PET-CT measure: Difference in transport rate (k1 to k2) on dynamic [18F]F-FAPI PET-CT between participants with malignant lesions and particpants with benign lesions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355414 id: IRB00385932 id: R33AT012317 type: NIH link: https://reporter.nih.gov/quickSearch/R33AT012317 briefTitle: Psilocybin in Chronic Low Back Pain and Depression overallStatus: RECRUITING date: 2024-04-22 date: 2026-07-30 date: 2026-08-30 date: 2024-04-09 date: 2024-04-23 name: Johns Hopkins University class: OTHER name: National Center for Complementary and Integrative Health (NCCIH) briefSummary: This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D).
nctId: NCT06355401 id: Soh-Med-24-03--06PD briefTitle: Maintenance Hormonal Therapy and DLBCL overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-03 date: 2029-03 date: 2024-04-09 date: 2024-04-09 name: Sohag University class: OTHER briefSummary: the study aims to detect the benefit of maintenance tamoxifen after achieving CR with conventional immuno-chemotherapy and/or radiotherapy in patients with DLDCL conditions: Diffuse Large B Cell Lymphoma studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Tamoxifen 20mg measure: disease free survival measure: overall survival measure: side effects sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355388 id: TRAGUSHF briefTitle: TRAnscutaneous vaGUS Nerve Stimulation in Patients With Chronic Heart Failure acronym: TRAGUS-HF overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2027-05-01 date: 2024-04-09 date: 2024-04-09 name: Fondazione Toscana Gabriele Monasterio class: OTHER name: Azienda Ospedaliera Città della Salute e della Scienza di Torino briefSummary: To verify the efficacy of transcutaneous vagus nerve stimulation (tVNS) on and autonomic balance in patients with chronic heart failure and reduced (HFrEF) or mildly reduced (HFmrEF) left ventricular ejection fraction. The study hypothesis is that tVNS increases baroreflex gain, with consequent benefits on sympathovagal balance (at short- and mid-term), and on quality of life and bio-humoral parameters (at mid-term). conditions: Heart Failure conditions: Heart Failure With Reduced Ejection Fraction conditions: Heart Failure With Midrange Ejection Fraction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: In order to maintain the 'double-blind,' at the end of the experimental protocol, the data acquired in each phase (baseline, active tVNS, placebo tVNS) will be saved in three different files, made unrecognizable by one of the investigators not involved in the tabulation and data analysis. A second investigator, unaware of the stimulation phases, will proceed with the tabulation of the data for each individual recording (three per patient). Only at the end of the study (or after recruiting 50% of patients for any interim analyses), will the investigators responsible for data analysis be revealed the corresponding phase for each recording. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 24 type: ESTIMATED name: Active tVNS name: Sham tVNS measure: Mean change in baroreflex gain (ms/mmHg) measure: Mean change in baroreflex gain (ms/mmHg) measure: Mean change in MSNA burst incidence (bursts/100 heartbeats) measure: Mean change in peak O2 consumption (mL/Kg/min) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Michele Emdin city: Pisa state: Pi zip: 56120 country: Italy name: Michele Emdin, MD, PhD role: CONTACT email: emdin@ftgm.it name: Francesco Gentile, MD role: SUB_INVESTIGATOR name: Claudio Passino, MD role: PRINCIPAL_INVESTIGATOR lat: 43.70853 lon: 10.4036 hasResults: False
nctId: NCT06355375 id: 02.24 briefTitle: Exercise in Pregnancy and Risk of Postpartum Depression overallStatus: RECRUITING date: 2024-03-22 date: 2025-01-01 date: 2025-12-01 date: 2024-04-09 date: 2024-04-09 name: Federico II University class: OTHER briefSummary: The prevalence of postpartum depression (PPD) varies between 11.9% and 19.2% during the perinatal period. PPD refers to minor and major depression incidents that occur during pregnancy or shortly after (up until 12 months after birth). The symptoms of PPD embrace feeling sad or having a depressed mood, being uninterested in the new-born, unreasonable crying and fear of injuring or harming the baby. Consequently, PPD can negatively impact the mother's well-being and the baby's development. The impact on a child can be short for cognitive and motor development . Although medication is a feasible alternative, many women have constraints due to continuing breastfeeding. Therefore, exercise can be an alternative that could help to deal with PPD. Exercise can be used as a preventive or treatment of mild depression at an early stage and as an addition to a treatment plan for major depressive disorder. Exercising during pregnancy and postpartum improves psychological health and also benefits physical fitness, weight gain control and the prevention or reduction of musculoskeletal discomfort and pain. Therefore, the American College of Obstetrics and Gynaecologists has recommended that women during pregnancy and postpartum engage in moderate-intensity physical activity almost every day for 30 min a day conditions: Depression conditions: Pregnancy Related studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Exercise during pregnancy primaryPurpose: PREVENTION masking: NONE count: 398 type: ESTIMATED name: exercise in pregnancy measure: edinburgh depression scale measure: Postpartum depression measure: preterm birth sex: FEMALE minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: Gabriele Saccone status: RECRUITING city: Naples zip: 80100 country: Italy name: Gabriele Saccone role: CONTACT phone: 0817461111 email: gabriele.saccone.1990@gmail.com lat: 40.85216 lon: 14.26811 hasResults: False
nctId: NCT06355362 id: HeCoMo briefTitle: Association of Intraoperative Hemodynamic Characteristics to Postoperative Complications and Mortality acronym: HeCoMo overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2025-06-30 date: 2024-04-09 date: 2024-04-22 name: Kliniken Essen-Mitte class: OTHER briefSummary: Worldwide, about 400 million major surgeries are performed annually. The scarce data available in the literature still suggest high postoperative morbidity and mortality, even in Europe. Data of the World Health Organization on causes of death suggest that death after surgery would be the number three cause of mortality if it were considered a separate cause of death. However, there is little structured or high-quality data on postoperative mortality in the literature.
In addition, the investigators aim to collect data on the structural characteristics of the study sites and, for each patient, characteristics of quality of perioperative care in order to analyze associations with hemodynamic characteristics and postoperative complications and mortalities. conditions: High-risk Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: Incidence of postoperative complications measure: Incidence of postoperative mortalities measure: Implementation rate of preoperative factors impacting postoperative outcome measure: Intraoperative hemodynamic characteristics measure: Postoperative haemodynamic characteristics measure: Co-morbidities of patients measure: Transfusion of blood components and administration of coagulation factors measure: Score of the physical/pathological activity status of the patients measure: Clinical frailty scale measure: Characteristics of perioperative care, time in perioperative units and the hospital measure: Characteristics of provision of anesthesia and type of pain therapy measure: Implementation rate of items perioperatively impacting outcome within an Enhanced-Recovery-After-Surgery pathway description sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355349 id: JW22101 briefTitle: To Evaluate the Safety and PK Characteristics in Healthy Volunteers overallStatus: COMPLETED date: 2023-04-28 date: 2023-07-10 date: 2023-07-17 date: 2024-04-09 date: 2024-04-09 name: JW Pharmaceutical class: INDUSTRY briefSummary: The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0101 and C2101 and administration of JW0102 in healthy volunteers under fasting conditions conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 46 type: ACTUAL name: Reference Drug or Test Drug measure: AUCt measure: Cmax sex: ALL minimumAge: 19 Years maximumAge: 55 Years stdAges: ADULT facility: Clinical Trial Center, Jeonbuk National University Hospital city: Jeonju country: Korea, Republic of lat: 35.82194 lon: 127.14889 hasResults: False